March 31, 2025 11:33 AM EDT

Lilly's heart disease drug could be dosed as little as once a year, study shows

Lei Lei Wu

News Reporter

Phase 2 results on Eli Lilly’s experimental heart disease drug showed it could be dosed far less frequently than competing treatments in development from Novartis …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Lilly's heart disease drug could be dosed as little as once a year, study shows

Lei Lei Wu

News Reporter

Sign up to read this article for free.

Executive Director, Marketing

Celldex Therapeutics

Hampton, NJ, USA

Firings sweep across FDA as former leaders lament the gutting of drug agency

RFK Jr. has long criticized drug ads. He just slashed the FDA office that regulates them

‘It’ll be a challenge’: BIO chief Crowley addresses seismic FDA overhaul

Big ambitions at Merck and AstraZeneca — along with a few giant pitfalls — reshape top ranks of the R&D 15

Sanofi continues its bet on R&D by poaching GSK’s head of development

Endpoints webinar: Inside the “One Lonza” strategy: Re-engineering the future of CDMO

Lil­ly's heart dis­ease drug could be dosed as lit­tle as once a year, study shows

News Reporter

Sign up to read this article for free.

Celldex Therapeutics

Hampton, NJ, USA

Lilly's heart disease drug could be dosed as little as once a year, study shows